Front Row Advisors’s ResMed RMD Stock Holding History

Front Row Advisors’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-14	Closed	-$3K	–	994
2020 Q2	$3K	Hold	14	–	–	﹤0.01%	788
2020 Q1	$2K	Buy	+14	New	+$2.23K	﹤0.01%	839

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Front Row Advisors's RMD Position: Q3 2020 in Review

Front Row Advisors sold out of ResMed (RMD) in Q3 2020, closing a stake of 14 shares — an estimated $3K sold.

Front Row Advisors first reported a position in RMD in Q1 2020 and held it in 2 quarters. The position peaked at $3K in Q2 2020. 626 funds tracked by Wall St. Rank hold RMD as of Q3 2020.

Front Row Advisors reported no remaining ResMed position as of Q3 2020 after selling out during the quarter.
Front Row Advisors sold 14 ResMed shares in Q3 2020, an estimated $3K.
Front Row Advisors first reported a position in ResMed in Q1 2020 and held it in 2 quarters.
Front Row Advisors's ResMed position peaked at $3K in Q2 2020.
626 funds tracked by Wall St. Rank held ResMed as of Q3 2020.

Based on Front Row Advisors's 13F filing for Q3 2020, filed 30 Nov 2020.